# US 2025/0084182 A1 · Antibody specific for mucin-1 and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084182 A1
- Document ID: US20250084182A1
- Status: Published application
- Kind: A1
- Application number: 18/621,926
- Filed: 2024-03-29
- Published: 2025-03-13
- Earliest claimed: 2020-07-31
- Assignees: R.P. Scherer Technologies, LLC
- Applicants: R.P. Scherer Technologies, LLC
- Inventors: David Rabuka; Penelope M. Drake; Yun Cheol Kim; Robyn M. Barfield; Maxine Bauzon; Ayodele Ogunkoya
- Web page: https://patentgrep.com/patent/US20250084182A1

## CPC

- C07K 16/3076: {against structure-related tumour-associated moieties}
- C07K 16/3092: {against tumour-associated mucins}
- A61K 47/6911: {the form being a liposome}
- A61K 2039/505: {comprising antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/524: CH2 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.

## Claims

### Claim 1

(canceled)

### Claim 2

A nucleic acid encoding a heavy chain variable domain (VH), a light chain variable domain (VL), or both, of an antibody that specifically binds to Mucin-1 (MUC-1),
wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), and a heavy chain complementarity determining region 3 (HCDR3) as set forth in a VH comprising the amino acid sequence of SEQ ID NO: 1, and
wherein the VL comprises a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) as set forth in a VL comprising the amino acid sequence of any one of SEQ ID NOs: 2, 3, or 4.

### Claim 3 (depends on 2)

The nucleic acid according to claim 2, wherein the VH comprises:
an HCDR1 comprising the amino acid sequence DHTMH (SEQ ID NO: 17);
an HCDR2 comprising the amino acid sequence YFYPRDDSTNYNEKFKG (SEQ ID NO: 18); and
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9); and
the VL comprises:
a) an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYAWSPPT (SEQ ID NO: 12); or
b) an LCDR1 comprising the amino acid sequence RASSSVGSSNLY (SEQ ID NO: 13),
an LCDR2 comprising the amino acid sequence RSTKLAS (SEQ ID NO: 14), and
an LCDR3 comprising the amino acid sequence HQYRWSPPT (SEQ ID NO: 15); or
c) an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYSWSPPT (SEQ ID NO: 16).

### Claim 4 (depends on 2)

The nucleic acid according to claim 2, wherein the VH comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 1.

### Claim 5 (depends on 4)

The nucleic acid according to claim 4, wherein the VL comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in any one of SEQ ID NO: 2, 3, or 4.

### Claim 6 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody comprises:
(i) HCDR1 comprising the amino acid sequence DHTMH (SEQ ID NO: 17),
an HCDR2 comprising the amino acid sequence YFYPRDDSTNYNEKFKG (SEQ ID NO: 18),
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYAWSPPT (SEQ ID NO: 12), as per Kabat definition; or
(ii) an HCDR1 comprising the amino acid sequence GYTFTDH (SEQ ID NO: 7),
an HCDR2 comprising the amino acid sequence YPRDDS (SEQ ID NO: 8),
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYAWSPPT (SEQ ID NO: 12), as per Chothia definition; or
(iii) an HCDR1 comprising the amino acid sequence GYTFTDHT (SEQ ID NO: 34),
an HCDR2 comprising the amino acid sequence FYPRDDST (SEQ ID NO: 44),
an HCDR3 comprising the amino acid sequence ARGLRYALDY (SEQ ID NO: 45),
an LCDR1 comprising the amino acid sequence SSVSSSY (SEQ ID NO: 33),
an LCDR2 comprising the amino acid sequence GT, and
an LCDR3 comprising the amino acid sequence HQYAWSPPT (SEQ ID NO: 12), as per IMGT definition.

### Claim 7 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody comprises:
(i) an HCDR1 comprising the amino acid sequence DHTMH (SEQ ID NO: 17), an HCDR2 comprising the amino acid sequence YFYPRDDSTNYNEKFKG (SEQ ID NO: 18),
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVGSSNLY (SEQ ID NO: 13),
an LCDR2 comprising the amino acid sequence RSTKLAS (SEQ ID NO: 14), and
an LCDR3 comprising the amino acid sequence HQYRWSPPT (SEQ ID NO: 15), as per Kabat definition, or
(ii) an HCDR1 comprising the amino acid sequence GYTFTDH (SEQ ID NO: 7),
an HCDR2 comprising the amino acid sequence YPRDDS (SEQ ID NO: 8),
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVGSSNLY (SEQ ID NO: 13),
an LCDR2 comprising the amino acid sequence RSTKLAS (SEQ ID NO: 14), and
an LCDR3 comprising the amino acid sequence HQYRWSPPT (SEQ ID NO: 15), as per Chothia definition; or
(iii) an HCDR1 comprising the amino acid sequence GYTFTDHT (SEQ ID NO: 34),
an HCDR2 comprising the amino acid sequence FYPRDDST (SEQ ID NO: 44),
an HCDR3 comprising the amino acid sequence ARGLRYALDY (SEQ ID NO: 45),
an LCDR1 comprising the amino acid sequence SSVGSSN (SEQ ID NO: 46),
an LCDR2 comprising the amino acid sequence RS, and
an LCDR3 comprising the amino acid sequence HQYRWSPPT (SEQ ID NO: 15), as per IMGT definition.

### Claim 8 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody comprises:
(i) an HCDR1 comprising the amino acid sequence DHTMH (SEQ ID NO: 17),
an HCDR2 comprising the amino acid sequence YFYPRDDSTNYNEKFKG (SEQ ID NO: 18);
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYSWSPPT (SEQ ID NO: 16), as per Kabat definition or
(ii) an HCDR1 comprising the amino acid sequence GYTFTDH (SEQ ID NO: 7),
an HCDR2 comprising the amino acid sequence YPRDDS (SEQ ID NO: 8),
an HCDR3 comprising the amino acid sequence GLRYALDY (SEQ ID NO: 9),
an LCDR1 comprising the amino acid sequence RASSSVSSSYLY (SEQ ID NO: 10),
an LCDR2 comprising the amino acid sequence GTSNLAS (SEQ ID NO: 11), and
an LCDR3 comprising the amino acid sequence HQYSWSPPT (SEQ ID NO: 16), as per Chothia definition; or
(iii) an HCDR1 comprising the amino acid sequence GYTFTDHT (SEQ ID NO: 34),
an HCDR2 comprising the amino acid sequence FYPRDDST (SEQ ID NO: 44),
an HCDR3 comprising the amino acid sequence ARGLRYALDY (SEQ ID NO: 45),
an LCDR1 comprising the amino acid sequence SSVSSSY (SEQ ID NO: 33),
an LCDR2 comprising the amino acid sequence GT, and
an LCDR3 comprising the amino acid sequence HQYSWSPPT (SEQ ID NO: 16), as per IMGT definition.

### Claim 9 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody is a humanized antibody or a chimeric antibody.

### Claim 10 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody is selected from the group consisting of: an IgG, Fv, single chain antibody, scFv, Fab, F(ab′)2, or Fab′.

### Claim 11 (depends on 10)

The nucleic acid according to claim 10, wherein the antibody is an IgG1 or a bispecific antibody.

### Claim 12 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody comprises a constant region comprising an amino acid sequence of a sulfatase motif.

### Claim 13 (depends on 2)

The nucleic acid according to claim 2, wherein the VH comprises the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the VL comprises the amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

### Claim 14 (depends on 2)

The nucleic acid according to claim 2, comprising a nucleic acid sequence as set forth in SEQ ID NO: 19 or a nucleic acid sequence having at least 80% sequence identity thereto.

### Claim 15 (depends on 14)

The nucleic acid according to claim 14, comprising a nucleic acid sequence as set forth in any one of SEQ ID NOs: 38, 39, or 40, or a nucleic acid sequence having at least 80% sequence identity of each thereto.

### Claim 16 (depends on 15)

The nucleic acid according to claim 15, wherein the antibody or fragment thereof comprises a constant region comprising an amino acid sequence of a sulfatase motif.

### Claim 17 (depends on 2)

The nucleic acid according to claim 2, wherein the antibody is a single chain antibody, and wherein the nucleic acid encodes the single chain antibody.

### Claim 18 (depends on 18)

The nucleic acid of claim 18, wherein the single chain antibody is an scFv.

### Claim 19 (depends on 2)

A recombinant expression vector comprising the nucleic acid of claim 2, wherein the nucleic acid is operably linked to a transcriptional control element that is active in a eukaryotic cell.

### Claim 20 (depends on 2)

A cell comprising the nucleic acid of claims 2.

### Claim 21 (depends on 19)

A cell comprising the expression vector of claim 19.

### Claim 22

A cell comprising:
a first nucleic acid encoding a VH of an antibody that specifically binds to MUC-1, wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO: 1; and
a second nucleic acid encoding a VL of the antibody, wherein the VL comprises a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of any one of SEQ ID NOs: 2, 3, or 4.

### Claim 23 (depends on 22)

The cell according to claim 22, comprising:
a first nucleic acid comprising a nucleic acid sequence as set forth in SEQ ID NO: 19 or a nucleic acid sequence having at least 80% sequence identity thereto; and
a second nucleic acid comprising a nucleic acid sequence as set forth in any one of SEQ ID NOs: 38, 39, or 40, or a nucleic acid sequence having at least 80% sequence identity of each thereto.

### Claim 24 (depends on 22)

The cell according to claim 22, comprising:
a first expression vector comprising the first nucleic acid; and
a second expression vector comprising the second nucleic acid.

### Claim 25

A fusion protein, comprising:
a VH, a VL, or both, of an antibody that specifically binds to MUC-1; fused to
a heterologous amino acid sequence,
wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO: 1, and
wherein the VL comprises a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of any one of SEQ ID NOs: 2, 3, or 4.
